Buscar en
Medicina Clínica (English Edition)
Toda la web
Inicio Medicina Clínica (English Edition) The pulse-mass index as a predictor of cardiovascular events in women with syste...
Journal Information
Vol. 148. Issue 2.
Pages 57-62 (January 2017)
Share
Share
Download PDF
More article options
Visits
4
Vol. 148. Issue 2.
Pages 57-62 (January 2017)
Original article
The pulse-mass index as a predictor of cardiovascular events in women with systemic lupus erythematosus
El índice pulso-masa como factor pronóstico de eventos cardiovasculares en mujeres con lupus eritematoso sistémico
Visits
4
Elsy Aidé García-Villegasa, Horacio Márquez-Gonzálezb,
Corresponding author
, Luis Felipe Flores-Suárezc, Antonio Rafael Villa-Romerod
a Departamento de Vigilancia Epidemiológica, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
b Departamento de Cardiopatías Congénitas, Hospital de Cardiología Centro Médico Nacional Siglo XXI, Mexico City, Mexico
c Clínica de Vasculitis, Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico
d Salud Pública, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City, Mexico
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (2)
Tables (2)
Table 1. Anthropometric, biochemical, clinical, dietary and medical treatment characteristics in patients with and without cardiovascular event in 2001 (n=238).
Table 2. Prevalence of risk factors for cardiovascular event in the total population, in women with and without CVE.
Show moreShow less
Abstract
Background

Patients with systemic lupus erythematosus (SLE) have 3times the risk of death compared to the rest of the population, with cardiovascular events (CVD) being one of the main causes. Indices such as waist-height (W-Ht I), waist-hip (W-Hp I) and pulse-mass (PMI) predict CVD, though the behaviour is unknown in patients with SLE. The aim of this study was to determine the prognostic value of PMI in the development of CVD in premenopausal women with SLE.

Methodology

Cohort study. Included were premenopausal women with SLE without prior CVD; excluded were those patients with antiphospholipid syndrome (APS), pregnancy, thyroid disease, recent liposuction, and chronic kidney disease. Exposure variables were: PMI, W-Ht I, W-Hp I and metabolic syndrome at onset of the cohort. Considered confounding variables were time of evolution, disease activity, cumulative damage and treatment. Through semi-annual appointments, accident and emergency admittance and hospitalization records the CVD were screened. Analysis was performed with Cox for proportional hazards and survival with Kaplan Meier.

Results

We included 238 women with a median age of 31 (18–52) years, with a follow-up of 8years. We identified 22 (9.6%) cases of CVD. In the Cox proportional hazards analysis, the prognostic variables were: PMI with HR=8.1 (95% CI: 1.1–65), metabolic syndrome with 2.4 (95% CI: 1–5.8), cumulative damage with HR=1.5 (95% CI: 1.1–2.2) and body fat percentage HR=2.8 (95% CI: 1.1–6.9).

Conclusions

The PMI is a better predictor factor of CVD in women with SLE.

Keywords:
Systemic lupus erythematosus
Cardiovascular disease
Traditional risk factors
Metabolic syndrome
Anthropometric
Pulse-mass index
Resumen
Antecedentes

Los enfermos de lupus eritematoso generalizado (LEG), comparados con el resto de la población, tienen 3 veces más riesgo de muerte; los eventos cardiovasculares (ECV) son una de las principales causas. Existen índices como cintura-talla (ICT), cintura-cadera (ICC) y el pulso-masa (IPM) que pronostican ECV; su comportamiento se desconoce en el LEG. El objetivo de este estudio fue determinar el valour pronóstico del IPM en el desarrollo de ECV en mujeres premenopáusicas con LEG.

Metodología

Estudio de cohorte. Se incluyó a mujeres premenopáusicas con LEG, sin ECV previo; se excluyó a las pacientes que presentaran síndrome antifosfolípido (SAF), que estuvieran embarazadas, con enfermedad tiroidea, liposucción reciente y enfermedad renal crónica.

Las variables de exposición fueron: IPM, ICT, ICC y síndrome metabólico al momento del ingreso a la cohorte. Se consideraron como variables confusoras el tiempo de evolución, actividad de la enfermedad, daño acumulado y tratamiento. Por medio de citas semestrales, registro de urgencias y hospitalización, se midieron los ECV.

Se utilizó análisis de riesgos proporcionales de Cox y sobrevida por Kaplan–Meier.

Resultados

Se incluyó a 238 mujeres con mediana de edad de 31 años (18-52), con seguimiento de 8 años. Se presentaron 22 casos (9,6%) de ECV. En el análisis de regresión de Cox las variables pronósticas fueron: IPM con HR=8,1 (IC95%: 1,1-65), síndrome metabólico con 2,4 (IC95%: 1-5,8), daño acumulado con HR=1,5 (IC95%: 1,1-2,2) y porcentaje de grasa corporal con HR=2,8 (IC95%: 1,1-6,9).

Conclusiones

El IPM es un buen factor pronóstico de ECV en mujeres con LEG.

Palabras clave:
Lupus eritematoso sistémico
Enfermedad cardiovascular
Factores de riesgo tradicionales
Síndrome metabólico
Antropometría
Índice pulso masa

Article

These are the options to access the full texts of the publication Medicina Clínica (English Edition)
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Medicina Clínica (English Edition)

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.medcle.2023.10.018
No mostrar más